← Patent-cliff monitor small molecule NUZOLVENCE ZOLIFLODACIN
Loss of exclusivity December 2035 FDA regulatory exclusivity expiry
Drug detail Brand name NUZOLVENCE Active ingredient ZOLIFLODACIN Strength 3GM/PACKET Dosage form FOR SUSPENSION Route ORAL Modality Small molecule FDA approval December 2025 Marketing status RX
Listed patents Patent Expires Type 9839641 January 2034 use U-4369 9540394 January 2034 use U-4369 9187495 January 2034 substance 8889671 January 2034 substance 8658641 June 2030 substance 9040528 October 2029 use U-4369
Regulatory exclusivity Code Expires GAIN December 2035 NCE December 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.